Please assess the completion status of the following clinical trial:

Trial Title: Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be healthy boys or girls, 11-17 years of age~* Must be a virgin with no intention of becoming sexually active during the study period~* Must have been properly vaccinated against diphtheria, tetanus and pertussis~Exclusion Criteria:~* Must not have received a vaccine against diphtheria, tetanus and pertussis in the past 5 years~* Must not have received any prior human papillomavirus (HPV) vaccine or meningococcal vaccine

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Concomitant Administration
- Group 2 (Type: EXPERIMENTAL): Non-concomitant administration

Based on this trial design, predict the completion outcome and termination type (if applicable).